JPRN-UMIN000052846CompletedUnknown
sefulness of belimumab in adult patients with systemic lupus erythematosus evaluated using single indexes: a meta-analysis and systematic review. - Usefulness of belimumab in adult patients with systemic lupus erythematosus evaluated using single indexes: a meta-analysis and systematic review.
Meiji Pharmaceutical University0 sites8,197 target enrollmentStarted: November 20, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Enrollment
- 8,197
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Other
Eligibility Criteria
- Ages
- 18years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •We exclude clinical studies that meet the following exclusion criteria: 1) not interventional studies; 2) non-original research articles such as reviews, case reports, letters, and research protocols; 3) no data description; 4) studies in children; 5) patients with lupus nephritis; 6) single-dose studies.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to investigate belimumab in IMGIdiopathic Membranous Glomerulonephropathy (IMGN)MedDRA version: 16.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy System Organ Class: 100000004857EUCTR2012-000385-38-GBGlaxoSmithKline Research and Development Ltd14
Active, not recruiting
Phase 1
Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus – BEAT LUPUSMedDRA version: 20.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2015-005543-14-GBniversity College London50
Active, not recruiting
Phase 1
A phase II trial of belimumab in combination withrituximab/venetoclax in patients with refractory orrelapsed chronic lymphocytic leukemiaRefractory or relapsed chronic lymphocytic leukemiaMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002622-87-DEniversity Hospital Tuebingen120
Recruiting
Phase 1
A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemiarefractory or relapsed chronic lymphocytic leukemiaMedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2024-511474-68-00niversitaetsklinikum Tuebingen AöR120
Not yet recruiting
Phase 2
Efficacy and safety of adalimumab in patients with peripheral spondyloarthritis without ankylosing spondylitis or psoriatic arthritis.NL-OMON32839Academisch Medisch Centrum40